BioCryst Pharmaceuticals (BCRX) Competitors

$9.60 +0.80 (+9.09%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$9.72 +0.12 (+1.20%)

As of 06:35 AM Eastern

BCRX vs. HALO, RGEN, ALKS, LGND, and CLDX

Should you buy BioCryst Pharmaceuticals stock or one of its competitors? MarketBeat compares BioCryst Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioCryst Pharmaceuticals include Halozyme Therapeutics (HALO), Repligen (RGEN), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), and Celldex Therapeutics (CLDX). These companies are all part of the "biotechnology" industry.

How does BioCryst Pharmaceuticals compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Halozyme Therapeutics has a net margin of 23.13% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Halozyme Therapeutics' return on equity of 187.91% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Halozyme Therapeutics presently has a consensus price target of $80.67, indicating a potential upside of 15.19%. BioCryst Pharmaceuticals has a consensus price target of $20.70, indicating a potential upside of 115.63%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Halozyme Therapeutics has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.51B	5.50	$316.89M	$2.78	25.19
BioCryst Pharmaceuticals	$885.72M	2.75	$263.86M	-$1.78	N/A

In the previous week, Halozyme Therapeutics had 12 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 30 mentions for Halozyme Therapeutics and 18 mentions for BioCryst Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 0.59 beat BioCryst Pharmaceuticals' score of 0.31 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Halozyme Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Halozyme Therapeutics beats BioCryst Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Repligen?

Repligen (NASDAQ:RGEN) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Repligen has a net margin of 6.73% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Repligen's return on equity of 4.88% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.73%	4.88%	3.48%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Repligen currently has a consensus price target of $169.62, indicating a potential upside of 58.47%. BioCryst Pharmaceuticals has a consensus price target of $20.70, indicating a potential upside of 115.63%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, BioCryst Pharmaceuticals had 12 more articles in the media than Repligen. MarketBeat recorded 18 mentions for BioCryst Pharmaceuticals and 6 mentions for Repligen. Repligen's average media sentiment score of 0.75 beat BioCryst Pharmaceuticals' score of 0.31 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.6% of Repligen shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Repligen has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Repligen. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	8.18	$48.89M	$0.90	118.92
BioCryst Pharmaceuticals	$885.72M	2.75	$263.86M	-$1.78	N/A

Summary

Repligen beats BioCryst Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Alkermes?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Alkermes has a net margin of 9.78% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Alkermes' return on equity of 9.26% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Alkermes	9.78%	9.26%	5.66%

BioCryst Pharmaceuticals currently has a consensus price target of $20.70, indicating a potential upside of 115.63%. Alkermes has a consensus price target of $45.40, indicating a potential upside of 16.68%. Given BioCryst Pharmaceuticals' higher possible upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Alkermes. MarketBeat recorded 18 mentions for BioCryst Pharmaceuticals and 16 mentions for Alkermes. Alkermes' average media sentiment score of 0.50 beat BioCryst Pharmaceuticals' score of 0.31 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

BioCryst Pharmaceuticals has higher earnings, but lower revenue than Alkermes. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$885.72M	2.75	$263.86M	-$1.78	N/A
Alkermes	$1.48B	4.39	$241.66M	$0.90	43.23

Summary

Alkermes beats BioCryst Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

BioCryst Pharmaceuticals presently has a consensus price target of $20.70, suggesting a potential upside of 115.63%. Ligand Pharmaceuticals has a consensus price target of $257.71, suggesting a potential upside of 16.50%. Given BioCryst Pharmaceuticals' higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Ligand Pharmaceuticals had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 19 mentions for Ligand Pharmaceuticals and 18 mentions for BioCryst Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.66 beat BioCryst Pharmaceuticals' score of 0.31 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 55.95% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Ligand Pharmaceuticals' return on equity of 16.19% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioCryst Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$885.72M	2.75	$263.86M	-$1.78	N/A
Ligand Pharmaceuticals	$268.09M	16.54	$124.45M	$7.37	30.01

BioCryst Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats BioCryst Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Celldex Therapeutics and Celldex Therapeutics both had 18 articles in the media. Celldex Therapeutics' average media sentiment score of 0.43 beat BioCryst Pharmaceuticals' score of 0.31 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celldex Therapeutics currently has a consensus target price of $49.78, indicating a potential upside of 53.12%. BioCryst Pharmaceuticals has a consensus target price of $20.70, indicating a potential upside of 115.63%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Celldex Therapeutics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,656.95	-$258.76M	-$4.26	N/A
BioCryst Pharmaceuticals	$885.72M	2.75	$263.86M	-$1.78	N/A

Celldex Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Celldex Therapeutics' return on equity of -50.72% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Summary

Celldex Therapeutics and BioCryst Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get BioCryst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCRX vs. The Competition

Export

Metric	BioCryst Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.24B	$3.04B	$6.30B	$12.20B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-5.39	18.86	21.03	25.58
Price / Sales	2.75	289.31	548.94	78.80
Price / Cash	7.11	56.53	42.94	55.34
Price / Book	-4.40	4.35	9.84	6.66
Net Income	$263.86M	$72.19M	$3.55B	$333.63M
7 Day Performance	7.87%	-1.05%	-0.52%	-0.12%
1 Month Performance	-0.72%	-0.02%	1.21%	3.93%
1 Year Performance	-2.54%	46.31%	41.24%	36.07%

BioCryst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCRX BioCryst Pharmaceuticals	3.7225 of 5 stars	$9.60 +9.1%	$20.70 +115.6%	-4.6%	$2.24B	$885.72M	N/A	530	News Coverage High Trading Volume
HALO Halozyme Therapeutics	3.9405 of 5 stars	$66.41 +3.6%	$79.11 +19.1%	+39.4%	$7.60B	$1.40B	26.67	390	Trending News Earnings Report Analyst Forecast Insider Trade High Trading Volume
RGEN Repligen	3.9494 of 5 stars	$115.91 -6.1%	$169.62 +46.3%	-18.6%	$6.96B	$738.26M	128.79	2,000
ALKS Alkermes	2.8147 of 5 stars	$35.47 +1.4%	$45.21 +27.5%	+26.2%	$5.83B	$1.48B	39.41	2,050	Analyst Downgrade Analyst Revision
LGND Ligand Pharmaceuticals	3.819 of 5 stars	$220.48 -0.4%	$257.71 +16.9%	+109.4%	$4.44B	$268.09M	29.92	80	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCRX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. HALO, RGEN, ALKS, LGND, and CLDX

How does BioCryst Pharmaceuticals compare to Halozyme Therapeutics?

Summary

How does BioCryst Pharmaceuticals compare to Repligen?

Summary

How does BioCryst Pharmaceuticals compare to Alkermes?

Summary

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

Summary

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. HALO, RGEN, ALKS, LGND, and CLDX

How does BioCryst Pharmaceuticals compare to Halozyme Therapeutics?

Is HALO or BCRX more profitable?

Do analysts recommend HALO or BCRX?

Which has preferable earnings & valuation, HALO or BCRX?

Does the media refer more to HALO or BCRX?

Which has more volatility & risk, HALO or BCRX?

Do institutionals and insiders believe in HALO or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Repligen?

Is RGEN or BCRX more profitable?

Do analysts rate RGEN or BCRX?

Does the media prefer RGEN or BCRX?

Do insiders & institutionals believe in RGEN or BCRX?

Which has more volatility & risk, RGEN or BCRX?

Which has higher valuation & earnings, RGEN or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Alkermes?

Is BCRX or ALKS more profitable?

Do analysts rate BCRX or ALKS?

Does the media prefer BCRX or ALKS?

Do institutionals & insiders believe in BCRX or ALKS?

Which has more risk & volatility, BCRX or ALKS?

Which has stronger valuation and earnings, BCRX or ALKS?

Summary

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

Do analysts recommend BCRX or LGND?

Does the media favor BCRX or LGND?

Is BCRX or LGND more profitable?

Do insiders and institutionals have more ownership in BCRX or LGND?

Which has preferable earnings and valuation, BCRX or LGND?

Which has more volatility and risk, BCRX or LGND?

Summary

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

Do institutionals and insiders have more ownership in CLDX or BCRX?

Does the media refer more to CLDX or BCRX?

Do analysts recommend CLDX or BCRX?

Which has more volatility and risk, CLDX or BCRX?

Which has stronger valuation & earnings, CLDX or BCRX?

Is CLDX or BCRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools